The content on this site is intended for healthcare professionals only
Dr Balar speaks with ecancertv at ESMO 2016 about the outcomes of patients receiving immune checkpoint therapy as a first line treatment against metastatic urothelial cancer.
You can read the news coverage of this story here.
These results advance on those of the IMvigor210 trial, described by Dr Balar at ASCO 2016.
Checkpoint therapy for metastatic urothelial cancer was also discussed by Dr Matthew Galsky.
ASCO 2026: Latest updates in mRCC
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
ESMO 2024: Optimising the personalisation of prostate cancer treatment
EAU 2024: Bladder cancer latest
Multiple myeloma in a resource constrained setting
Choosing Wisely in radiology Tanzania
Molecular profiling in prostate cancer: key challenges for clinical implementation
